Back to Search
CHARLES CHESNUT, DO, MS
DO, MS
Surgery Physician
NPI: 1972823532IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
DO1999(NV)
CMS Specialties
PrimaryGENERAL SURGERY
Education
LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE, ERIE
Class of 2010
Research & Publications (20)
Salmon calcitonin: a review of current and future therapeutic indications.
PMID 18071651·Osteoporos Int·2008
6-review
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
PMID 18056047·Ann N Y Acad Sci·2007
6-review
Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease.
PMID 17531778·Biol Blood Marrow Transplant·2007
4-observational
Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.
PMID 16903769·Drugs·2006
6-review
Denosumab in postmenopausal women with low bone mineral density.
PMID 16495394·N Engl J Med·2006
3-trial
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
PMID 15811208·Curr Med Res Opin·2005
3-trial
Review of treatment modalities for postmenopausal osteoporosis.
PMID 16295815·South Med J·2005
6-review
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
PMID 16059627·J Bone Miner Res·2005
7-preclinical
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
PMID 15977464·Aging Clin Exp Res·2005
3-trial
Short-term calcium supplementation has no effect on biochemical markers of bone remodeling in early postmenopausal women.
PMID 14648073·Arch Gynecol Obstet·2004
3-trial
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
PMID 15231010·J Bone Miner Res·2004
3-trial
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
PMID 15121021·Bone·2004
3-trial
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
PMID 15071723·Osteoporos Int·2004
3-trial
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
PMID 14753731·J Bone Miner Res·2004
3-trial
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
PMID 14727011·Osteoporos Int·2004
3-trial
Bone remodeling and bone mineral density during pregnancy.
PMID 14504876·Arch Gynecol Obstet·2003
8-other
In vivo assessment of architecture and micro-finite element analysis derived indices of mechanical properties of trabecular bone in the radius.
PMID 11878456·Osteoporos Int·2002
4-observational
Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
PMID 12107665·Osteoporos Int·2002
3-trial
Diagnosis of postmenopausal osteoporosis: reviews in endocrine and metabolic disorders.
PMID 11704977·Rev Endocr Metab Disord·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5320 S RAINBOW BLVD STE 302
LAS VEGAS, NV 89118 - Phone
- (702) 853-3300
Quick Facts
- NPI
- 1972823532
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 16
- Publications
- 20
Are you this provider?
Claim Your Profile